SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL

被引:51
作者
Sattler, M [1 ]
Verma, S
Pride, YB
Salgia, R
Rohrschneider, LR
Griffin, JD
机构
[1] Harvard Univ, Sch Med, Dept Adult Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA
关键词
D O I
10.1074/jbc.M006250200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SHIP1 is an SH2 domain containing inositol-5-phosphatase that appears to be a negative regulator of hematopoiesis, The tyrosine kinase oncogene BCR/ABL drastically reduces expression of SHIP1. The major effect of re-expressing SHIP1 in BCR/ABL-transformed cells is reduction of hypermotility, To investigate the potential signaling pathways involving SHIP1 in hematopoietic cells, we overexpressed SHIP1 in a murine BCR/ABL-transformed Ba/F3 cell line and identified SHIP1-associated proteins. SHIP1 was found to form a novel signaling complex with BCR/ABL that includes DOK1 (p62(DOK)), phosphatidylinositol 3-kinase (PI3K), and CRKL, each of which has been previously shown to regulate migration in diverse cell types. We found that DOK1 binds directly through its PTB domain to SHIP1. Direct interaction of SHIP1 with CRKL was mediated through the CRKL-SH2 domain. Go-precipitation experiments suggest that Tyr(917) and Tyr(1020) in SHIP1 are likely to mediate interactions with DOK1, In contrast to wild type SHIP1, expression of tyrosine mutant SHIP1 by transient transfection did not alter migration. PI3K was likely linked to this complex by CRKL, Thus, this complex may serve to generate a very specific set of phosphoinositol products, possibly involved in regulating migration. Overall, these data suggest that proteins that interact with SHIP1 through Tyr(917) and Tr-1020, such as DOK1 and SHC, are likely to be involved in the regulation of SHIP1 dependent migration.
引用
收藏
页码:2451 / 2458
页数:8
相关论文
共 60 条
[41]   ASSOCIATION OF THE SHC AND GRB2/SEM5 SH2-CONTAINING PROTEINS IS IMPLICATED IN ACTIVATION OF THE RAS PATHWAY BY TYROSINE KINASES [J].
ROZAKISADCOCK, M ;
MCGLADE, J ;
MBAMALU, G ;
PELICCI, G ;
DALY, R ;
LI, W ;
BATZER, A ;
THOMAS, S ;
BRUGGE, J ;
PELICCI, PG ;
SCHLESSINGER, J ;
PAWSON, T .
NATURE, 1992, 360 (6405) :689-692
[42]   BCR/ABL induces multiple abnormalities of cytoskeletal function [J].
Salgia, R ;
Li, JL ;
Ewaniuk, DS ;
Pear, W ;
Pisick, E ;
Burky, SA ;
Ernst, T ;
Sattler, M ;
Chen, LB ;
Griffin, JD .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (01) :46-57
[43]  
Sattler M, 1999, MOL CELL BIOL, V19, P7473
[44]   Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells [J].
Sattler, M ;
Salgia, R .
LEUKEMIA, 1998, 12 (05) :637-644
[45]  
Sattler M, 1997, J BIOL CHEM, V272, P10248
[46]   The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors [J].
Sattler, M ;
Salgia, R ;
Shrikhande, G ;
Verma, S ;
Choi, JL ;
Rohrschneider, LR ;
Griffin, JD .
ONCOGENE, 1997, 15 (19) :2379-2384
[47]  
Sattler M, 1996, ONCOGENE, V12, P839
[48]   Differential signaling after beta 1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1) [J].
Sattler, M ;
Salgia, R ;
Shrikhande, G ;
Verma, S ;
Uemura, P ;
Law, SF ;
Golemis, EA ;
Griffin, JD .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (22) :14320-14326
[49]  
Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0
[50]   SHIP-mediated inhibition of K562 erythroid differentiation requires an intact catalytic domain and Shc binding site [J].
Siegel, J ;
Li, Y ;
Whyte, P .
ONCOGENE, 1999, 18 (50) :7135-7148